JAGX · Jaguar Health Inc. Common Stock
View on chartInsiders & Stakes
| Lisa A. Conte CEO and President | ▲ Buy | Grant | 29,258 Shares held | 12/11/2025 | View profile |
| Divis Gregory J Director | ▲ Buy | Option Exercise | 12,133 Shares held | 5/18/2022 | View profile |
| Jonathan S. Wolin Chief of Staff, CCO & GC | ▲ Buy | Grant | 11,938 Shares held | 12/11/2025 | View profile |
| Pravin R. Chaturvedi Chief Scientific Officer | ▲ Buy | Grant | 11,938 Shares held | 12/11/2025 | View profile |
| Carol R. Lizak Chief Financial Officer | ▲ Buy | Grant | 11,911 Shares held | 12/11/2025 | View profile |
| Steven R. King Chief of Sustainable Supply | ▲ Buy | Grant | 11,885 Shares held | 12/11/2025 | View profile |
| John Micek Director | ▲ Buy | Grant | 7,430 Shares held | 12/11/2025 | View profile |
| Jonathan B. Siegel Director | ▲ Buy | Grant | 7,423 Shares held | 12/11/2025 | View profile |
| James J. Bochnowski Director | ▲ Buy | Grant | 6,415 Shares held | 12/11/2025 | View profile |
| Anula Jayasuriya Director | ▲ Buy | Grant | 5,916 Shares held | 12/11/2025 | View profile |
Transaction History
| James J. Bochnowski | ▲ Buy | Grant | 6,363 | $0 | 12/11/2025 |
| Jonathan B. Siegel | ▲ Buy | Grant | 7,377 | $0 | 12/11/2025 |
| Anula Jayasuriya | ▲ Buy | Grant | 5,870 | $0 | 12/11/2025 |
| Carol R. Lizak | ▲ Buy | Grant | 11,740 | $0 | 12/11/2025 |
| John Micek | ▲ Buy | Grant | 7,377 | $0 | 12/11/2025 |
| Steven R. King | ▲ Buy | Grant | 11,740 | $0 | 12/11/2025 |
| Lisa A. Conte | ▲ Buy | Grant | 28,592 | $0 | 12/11/2025 |
| Jonathan S. Wolin | ▲ Buy | Grant | 11,740 | $0 | 12/11/2025 |
| Pravin R. Chaturvedi | ▲ Buy | Grant | 11,740 | $0 | 12/11/2025 |
| Lisa A. Conte | ▲ Buy | Option Exercise | 2 | — | 5/17/2025 |
| Steven R. King | ▲ Buy | Option Exercise | 1 | — | 5/17/2025 |
| Jonathan S. Wolin | ▲ Buy | Grant | 4,922 | $0 | 10/8/2024 |
| Carol R. Lizak | ▲ Buy | Grant | 4,280 | $0 | 10/8/2024 |
| Pravin R. Chaturvedi | ▲ Buy | Grant | 4,922 | $0 | 10/8/2024 |
| Lisa A. Conte | ▲ Buy | Grant | 16,503 | $0 | 10/8/2024 |
| Steven R. King | ▲ Buy | Grant | 4,922 | $0 | 10/8/2024 |
| Pravin R. Chaturvedi | ▲ Buy | Option Exercise | 871 | — | 5/17/2024 |
| Jonathan S. Wolin | ▲ Buy | Option Exercise | 871 | — | 5/17/2024 |
| Carol R. Lizak | ▲ Buy | Option Exercise | 431 | — | 5/17/2024 |
| Steven R. King | ▲ Buy | Option Exercise | 612 | — | 5/17/2024 |
| Lisa A. Conte | ▲ Buy | Option Exercise | 2,695 | — | 5/17/2024 |
| Pravin R. Chaturvedi | ▲ Buy | Option Exercise | 134 | — | 4/5/2024 |
| Jonathan S. Wolin | ▲ Buy | Option Exercise | 89 | — | 4/5/2024 |
| Carol R. Lizak | ▲ Buy | Option Exercise | 60 | — | 4/5/2024 |
| Steven R. King | ▲ Buy | Option Exercise | 178 | — | 4/5/2024 |
| Lisa A. Conte | ▲ Buy | Option Exercise | 600 | — | 4/5/2024 |
| Jonathan S. Wolin | ▲ Buy | Grant | 196,628 | $0 | 8/14/2023 |
| Anula Jayasuriya | ▲ Buy | Grant | 68,568 | $0 | 8/14/2023 |
| Jonathan B. Siegel | ▲ Buy | Grant | 68,568 | $0 | 8/14/2023 |
| John Micek | ▲ Buy | Grant | 68,568 | $0 | 8/14/2023 |
| James J. Bochnowski | ▲ Buy | Grant | 76,613 | $0 | 8/14/2023 |
| Pravin R. Chaturvedi | ▲ Buy | Grant | 204,192 | $0 | 8/14/2023 |
| Carol R. Lizak | ▲ Buy | Grant | 142,088 | $0 | 8/14/2023 |
| Steven R. King | ▲ Buy | Grant | 159,168 | $0 | 8/14/2023 |
| Lisa A. Conte | ▲ Buy | Grant | 383,605 | $0 | 8/14/2023 |
| Anula Jayasuriya | ▲ Buy | Grant | 1,718 | $0 | 7/1/2023 |
| Pravin R. Chaturvedi | ▲ Buy | Option Exercise | 870 | — | 5/17/2023 |
| Jonathan B. Siegel | ▲ Buy | Option Exercise | 1,145 | — | 5/17/2023 |
| John Micek | ▲ Buy | Option Exercise | 1,145 | — | 5/17/2023 |
| James J. Bochnowski | ▲ Buy | Option Exercise | 1,280 | — | 5/17/2023 |
| Jonathan S. Wolin | ▲ Buy | Option Exercise | 871 | — | 5/17/2023 |
| Carol R. Lizak | ▲ Buy | Option Exercise | 431 | — | 5/17/2023 |
| Steven R. King | ▲ Buy | Option Exercise | 611 | — | 5/17/2023 |
| Lisa A. Conte | ▲ Buy | Option Exercise | 2,694 | — | 5/17/2023 |
| Pravin R. Chaturvedi | ▲ Buy | Option Exercise | 44 | — | 4/5/2023 |
| Carol R. Lizak | ▲ Buy | Option Exercise | 60 | — | 4/5/2023 |
| Jonathan S. Wolin | ▲ Buy | Option Exercise | 88 | — | 4/5/2023 |
| Steven R. King | ▲ Buy | Option Exercise | 177 | — | 4/5/2023 |
| Lisa A. Conte | ▲ Buy | Option Exercise | 600 | — | 4/5/2023 |
| Jonathan S. Wolin | ▲ Buy | Open Market | 317 | $10 | 12/31/2022 |
| James J. Bochnowski | ▲ Buy | Option Exercise | 13,133 | — | 5/18/2022 |
| Divis Gregory J | ▲ Buy | Option Exercise | 12,133 | — | 5/18/2022 |
| Jonathan B. Siegel | ▲ Buy | Option Exercise | 12,133 | — | 5/18/2022 |
| John Micek | ▲ Buy | Option Exercise | 12,133 | — | 5/18/2022 |
| Pravin R. Chaturvedi | ▲ Buy | Option Exercise | 3,333 | — | 4/5/2022 |
| Carol R. Lizak | ▲ Buy | Option Exercise | 4,513 | — | 4/5/2022 |
| Jonathan S. Wolin | ▲ Buy | Option Exercise | 6,666 | — | 4/5/2022 |
| Steven R. King | ▲ Buy | Option Exercise | 13,333 | — | 4/5/2022 |
| Lisa A. Conte | ▲ Buy | Option Exercise | 45,000 | — | 4/5/2022 |
| Carol R. Lizak | ▲ Buy | Open Market | 7,968 | $20K | 9/13/2021 |
| Lisa A. Conte | ▲ Buy | Open Market | 7,968 | $20K | 9/13/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
JAGX Announces Stock Dividend, Crofelemer Study Presentations
Jaguar Health announced a special stock dividend, giving shareholders additional shares. The company also has two Crofelemer studies accepted for presentation at the American College of Gastroenterology meetings, providing early data on the drug’s use in short bowel syndrome. These events highlight ongoing progress in Jaguar’s product pipeline and shareholder value.
JAGX Announces Stock Dividend, Crofelemer Study Presentations. Jaguar Health announced a special stock dividend, giving shareholders additional shares. The company also has two Crofelemer studies accepted for presentation at the American College of Gastroenterology meetings, providing early data on the drug’s use in short bowel syndrome. These events highlight ongoing progress in Jaguar’s product pipeline and shareholder value.